Full Description
This book presents the
current state of knowledge regarding the ability of Helicobacter pylori to colonize the gastrointestinal tract, the
global epidemiology of H. pylori
infection, transmission routes, the pathophysiology of H. pylori-related gastroduodenal and other diseases, diagnosis and
treatment methods, guidelines for eradication, antibiotic resistance, the
reinfection rate after H. pylori eradication,
and animal models of H. pylori or
related Helicobacter infection. The
aim is to equip readers around the world with the understanding required in
order to implement effective methods of H.
pylori eradication and to enhance clinical outcomes for patients. The text
is clearly written and is complemented by many helpful illustrations. This book
will be a great asset in clinical practice for all practitioners who are
involved in caring for patients with H.
pylori-related diseases or have an interest in the subject. It will also be
a useful source of information for medical students and for intelligent laypeople
seeking information on H. pylori.
Contents
Part 1. Epidemiology-Prevalence and
Transmission routes of H. pylori.- Part 2. Pathophysiology.- 1) Colonization of
H. pylori in the stomach.- 2) Brief description of Pathophysiology.- 3) Immune
mechanism.- 4) Change of acid secretion, ghrelin and leptin by H. pylori.- 5) H.
pylori virulence factors.- A: toxin (CagA, VacA, DupA, OipA, IceA).- B: genetic
polymorphism of toxin and disease.- 6) Host factors: genetic polymorphism,
etc.- Part 3. Diagnosis.- 1) Serology.- 2) Histology.- 3) Culture.- 4) UBT.- 5)
Stool antigen.- 6) Specific conditions.- A: Children.- B: Bleeding.- Part
4. Symptom.- 1)Symptom of acute and chronic H. pylori infection.- Part 5.
Disease.- 1) Atrophic gastritis and Intestinal metaplasia.- 2) Functional dyspepsia.-
3) Peptic ulcer.- 4) MALToma.- 5) Gastric cancer.- A: Synopsis and Epidemiology
of gastric cancer.- B1: Pathogenesis: i.Genetic alternation (mutations in
tumor-related genes) induced by Activation-induced cytidine deaminase (AID).- B2:
Pathogenesis: ii. Epigenetic mechanisms: aberrant DNA methylation, microRNA.- B3:
Pathogenesis:iii. Macrophage inhibitory factor (MIF).- B4: Pathogenesis: iv.
Epidermal mesenchyme transition (EMT).- B5: Pathogenesis: v. ABO blood type.- B6:
Pathogenesis: vi. First relatives of gastric cancer.- C: H. pylori-negative
gastric cancer.- 6) Gastroesophageal reflux disease (GERD).- 7) NSAID-induced
gastropathy and H. pylori infection.- 8) Extraintestinal manifestations of H.
pylori infection.- A: Iron deficiency anemia.- B: Idiopathic thrombocytopenic
purpura.- C: Heart disease.- D: Atopy and allergy.- Part 6. Antibiotic
resistance.- 1) Synopsis of antibiotic resistance.- 2) Clarithromycin.- 3)
Amoxicillin.- 4) Quinolone.- 5) Metronidazole.- Part 7. Treatment.- 1) Synopsis
of antibiotic treatment.- 2) Triple therapy.- 3) Quadruple therapy.- 4)
Sequential therapy.- 5) Concomitant therapy.- 6) Tailored therapy based on
antibiotic resistance.- 7) Levofloxacin or rifabutin based triple therapy.- 8)
Probiotics.- 9) Treatment guidelines.- 10) Screening method of early gastric
cancer.- 11) Recrudescence and reinfection.- Part 8. Consequences of H.
pylori eradication.- 1) Peptic ulcer disease.- 2) atrophic gastritis and
Intestinal metaplasia.- 3) Gastric cancer.- Part 9. The effect of H. pylori on
the other microbiota of stomach.- The effect of H. pylori on the other
microbiota of stomach.- Part 10. Animal model- H. pylori, H. felis.
